Research has generated several hypotheses for explaining the underlying pathophysiology of schizophrenia. This video focuses on dysfunction in dopaminergic signaling as a basis for positive symptoms and dysfunction in glutamatergic signaling as a mechanism for negative and cognitive symptoms.
Related content
In this video Professor Christoph Correll discusses the challenges with available schizophrenia treatments & what clinicians should keep in mind when considering the emerging treatment options for schizophrenia.
The table summarizes the high-level clinical characteristics of the existing and newly emerging pharmacological treatments for schizophrenia with at least one positive placebo-controlled trial.
LDT=Laterodorsal tegmental nucleus; NAc = Nucleus Accumbens; SN = Substantia Nigra; VTA = Ventral Tegmental Area.